Spark Therapeutics Inc

Most Recent

  • uploads///Graph
    Company & Industry Overviews

    Most Analysts Have Given bluebird bio Positive Ratings in March

    Wall Street analysts expect a potential upside of 19.21% for bluebird bio (BLUE) based on the company’s closing price on March 27.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    A Look at Spark’s Potential Revenue Contribution to Roche Holdings

    Wall Street analysts have projected Spark Therapeutics’ revenues to be $105.64 million, $169.22 million, and $263.76 million for fiscal 2019, fiscal 2020, and fiscal 2021, respectively.

    By Margaret Patrick
  • uploads///merger _
    Healthcare

    Roche Holdings to Acquire Spark Therapeutics

    On February 25, Roche Holdings (RHHBY) issued a press release announcing that it has entered a definitive agreement to acquire Spark Therapeutics (ONCE).

    By Margaret Patrick
  • uploads///SGMO net loss
    Company & Industry Overviews

    How Are Sangamo Therapeutics’ Earnings and Expenses Trending?

    In the first nine months of 2018, Sangamo Therapeutics (SGMO) reported net income of -$49.7 million compared to -$41.5 million in the same period the prior year.

    By Daniel Collins
  • uploads///red blood cells _
    Company & Industry Overviews

    uniQure Stock Rose 35.7% Yesterday—Here’s Why

    On November 15, uniQure (QURE) stock closed at $30.93, which reflected a ~35.66% rise from its previous day’s close of $22.80.

    By Daniel Collins
  • uploads///EDIT
    Company & Industry Overviews

    Editas Stock: Analysts’ Recommendations

    In November, among the ten analysts covering Editas Medicine (EDIT), six analysts recommended a “buy,” while four recommended a “hold.”

    By Kenneth Smith
  • uploads///Spark ana reco
    Company & Industry Overviews

    What Spark Therapeutics’ Valuation Trend Indicates

    Spark Therapeutics’ (ONCE) operating expenses decreased from $78.48 million in Q2 2017 to $59.78 million in Q2 2018.

    By Kenneth Smith
  • uploads///Spark pipeline
    Company & Industry Overviews

    How Spark Therapeutics Is Positioned in 2018

    Spark Therapeutics generated revenues of $25.18 million in the second quarter of 2018 compared to $1.48 million in Q2 2017.

    By Kenneth Smith
  • uploads///blood _
    Company & Industry Overviews

    BioMarin Pharmaceutical and Its Promising Research Pipeline

    Stocks focused on gene therapy have garnered strong investor interest in 2018. In this series, we’ll analyze four of those companies.

    By Kenneth Smith
  • uploads///virus _
    Company & Industry Overviews

    Analysts Are Mostly Positive on Intellia Therapeutics This Month

    On September 10, Intellia Therapeutics stock closed at $26.98, a ~0.95% fall from the previous day’s close of $27.24.

    By Daniel Collins
  • uploads///dna _
    Earnings Report

    How Analysts Rate Editas Medicine and Peers in August

    Editas Medicine (EDIT) is a research-stage genome editing company. Five of the total nine analysts covering the company in August have given the stock a “buy” rating.

    By Kenneth Smith
  • uploads///joshua coleman  unsplash
    Company & Industry Overviews

    Why Achaogen Stock Fell Steeply Yesterday

    Yesterday, Achaogen (AKAO) announced that the FDA had approved its antibacterial agent, Zemdri (plazomicin), for adults suffering from complicated urinary tract infections (or cUTI) who don’t have significant treatment options.

    By Margaret Patrick
  • uploads///dna _
    Healthcare

    Why Axovant Sciences Stock Jumped ~160% on Wednesday

    Axovant Sciences (AXON) stock jumped ~160.0% to the closing price of $4.55 on June 6.

    By Mike Benson
  • uploads///Analysts
    Earnings Report

    Recent Developments, Recommendations for JAZZ in May

    In May, Jazz Pharmaceuticals (JAZZ) submitted a supplemental new drug application to the FDA for the label expansion of Xyrem.

    By Daniel Collins
  • uploads///pills _
    Company & Industry Overviews

    Analysts’ Ratings for Sarepta Therapeutics and Peers in April

    Of the 19 analysts covering Sarepta Therapeutics in April 2018, six analysts gave the stock a “strong buy” rating.

    By Kenneth Smith
  • uploads///rawpixel com  unsplash
    Company & Industry Overviews

    How Analysts View Tetraphase Pharmaceuticals in April 2018

    Of eight analysts tracking Tetraphase Pharmaceuticals, one analyst rated it as a “strong buy,” and six analysts gave it a “buy” rating.

    By Kenneth Smith
  • uploads///ONCE
    Company & Industry Overviews

    Exploring Spark Therapeutics’ Cash Flows

    Spark Therapeutics (ONCE) used $154.5 million in operating activities in 2017 compared to $80.4 million in 2016.

    By Kenneth Smith
  • uploads///ONCE
    Company & Industry Overviews

    Exploring Spark Therapeutics’ Product Pipeline

    Spark Therapeutics’ Luxturna was approved by the FDA in December 2017. It’s the first gene therapy approved for the treatment of a genetic disease.

    By Kenneth Smith
  • uploads///cells _
    Company & Industry Overviews

    Analysts’ Ratings for Spark Therapeutics and Its Peers in April 2018

    Of the 20 analysts covering Spark Therapeutics in April 2018, four have given the stock “strong buy” recommendations.

    By Kenneth Smith
  • uploads///mental health _
    Company & Industry Overviews

    Analysts Rate Voyager Therapeutics and Its Peers in April

    Voyager Therapeutics is a clinical-stage gene therapy company with a focus on developing treatments for severe neurological diseases.

    By Kenneth Smith
  • uploads///Spark Therapeutics
    Company & Industry Overviews

    Why Spark Therapeutics Stock Rose in the Week Ended March 29

    On March 29, 2018, Spark Therapeutics was trading at $66.59, which represented a ~62% increase from its 52-week low of $41.06.

    By Daniel Collins
  • uploads///Chart
    Earnings Report

    What Investors Should Know about Pfizer’s Recent Developments

    The recent developments for Pfizer (PFE) include various product developments, pipeline developments, and commercial developments.

    By Mike Benson
    • CONNECT with Market Realist
    • Link to Facebook
    • Link to Twitter
    • Link to Instagram
    • Link to Email Subscribe
    Market Realist Logo
    Do Not Sell My Personal Information

    © Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.